Proactive Investors interview with Chairman
Chairman gave interview to Proactive Investors about M&A activity in neuroscience sector.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Therapeutics (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces that Dennis Purcell, Chairman of the Company, has recently given an interview to Proactive Investors about the increasing mergers and acquisitions activity in the neuroscience sector. The interview can be viewed at https://www.proactiveinvestors.co.uk/companies/news/1065372/solvonis-therapeutics-chairman-on-the-future-of-biotech-neuroscience-ma.html.
| www.solvonis.com | X (formerly Twitter) |
About Reach announcements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.